Action Vickers Vantage Corporat... - VCKA

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

9,01

Prix Achat

10,20

Prix Vente

10,38

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

1,405B

Clôture Veille

9,01

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

155 943 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,48

Bénéfice par action (BPA)

-0,73

Chiffre d'affairess

46,74M

Bénéfice net

-114,33M

Vickers Vantage Corp I is a blank check company. Vickers Vantage Corp I is a blank check company.

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.scilexholding.com

Siège social

Wilmington, Delaware, USA

Fondé

Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on F

SEC declared Effectiveness of Vickers’s registration statement on Form S-4Extraordinary General Meeting of...

Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)

SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent...

Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa

PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial...

Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topica

30 million lives now covered by one of the largest national PBMsContinue to work with this PBM to access an...

Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.

Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in...

Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or...

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful...

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes

SAN DIEGO and PALO ALTO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a...

Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group...

Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination betwee

PALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

VCKA - Frequently Asked Questions (FAQ)

What is the current Vickers Vantage Corporat... share price?

The current share price of Vickers Vantage Corporat... is US$ 9,01

How many Vickers Vantage Corporat... shares are in issue?

Vickers Vantage Corporat... has 155 943 000 shares in issue

What is the market cap of Vickers Vantage Corporat...?

The market capitalisation of Vickers Vantage Corporat... is USD 1,41B

What is the 1 year trading range for Vickers Vantage Corporat... share price?

Vickers Vantage Corporat... has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Vickers Vantage Corporat...?

The price to earnings ratio of Vickers Vantage Corporat... is -0,48

What is the cash to sales ratio of Vickers Vantage Corporat...?

The cash to sales ratio of Vickers Vantage Corporat... is 1,17

What is the reporting currency for Vickers Vantage Corporat...?

Vickers Vantage Corporat... reports financial results in USD

What is the latest annual turnover for Vickers Vantage Corporat...?

The latest annual turnover of Vickers Vantage Corporat... is USD 46,74M

What is the latest annual profit for Vickers Vantage Corporat...?

The latest annual profit of Vickers Vantage Corporat... is USD -114,33M

What is the registered address of Vickers Vantage Corporat...?

The registered address for Vickers Vantage Corporat... is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Vickers Vantage Corporat... website address?

The website address for Vickers Vantage Corporat... is www.scilexholding.com

Which industry sector does Vickers Vantage Corporat... operate in?

Vickers Vantage Corporat... operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
JTAIJet AI Inc	US$ 6,02 (133,33%)	104,48M
SRMSRM Entertainment Inc	US$ 0,6999 (95,50%)	254,39M
WRDWeRide Inc	US$ 31,4877 (83,39%)	21,07M
INLFINLIF Limited	US$ 16,27 (80,58%)	7,68M
MBRXMoleculin Biotech Inc	US$ 2,1201 (66,94%)	136,66M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3,08 (-56,31%)	425,19k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3,36 (-52,68%)	5,21k
CSAICloudastructure Inc	US$ 19,0001 (-49,58%)	1,01M
NEXNNexxen International Ltd	US$ 10,30 (-49,16%)	160,99k
BSLKBolt Projects Holdings Inc	US$ 0,6626 (-46,13%)	13,07M
CNSPCNS Pharmaceuticals Inc	US$ 0,1415 (31,26%)	489,28M
MGOLMGO Global Inc	US$ 0,7176 (-15,08%)	417,31M
SRMSRM Entertainment Inc	US$ 0,6999 (95,50%)	254,39M
INTCIntel Corporation	US$ 23,60 (-2,20%)	230,26M
NVDANVIDIA Corporation	US$ 138,85 (2,63%)	194,99M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vickers Vantage Corporation I (VCKA)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Vickers Vantage Corporation I

VCKA Dernières nouvelles

Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on F

Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)

Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa

Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topica

Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.

Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes

Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination betwee

VCKA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vickers Vantage Corporation I (VCKA) Cours

Vickers Vantage Corporation I (VCKA)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Vickers Vantage Corporation I

VCKA Dernières nouvelles

Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on F

Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)

Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa

Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topica

Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.

Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes

Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination betwee

VCKA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS